Company Profile
Alnylam Pharmaceuticals, Inc. Stock Price, News & Analysis
- Ticker:
- ALNY
- Exchange:
- NASDAQ
- Sector:
- Nucleic Acid Drugs
- Location:
- Cambridge, Massachusetts
Stock performance
216.12 USD (-5.51%)
Close
Last updated: August 6, 2026
38.2B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ALNY closed down 5.51% at $216.12. No new same-company headline was identified in the current news window.
Company overview
Business overview
Alnylam Pharmaceuticals is the pioneer of RNA interference therapeutics and one of the most important platform biotech companies in the market. Its approved medicines and pipeline programs focus on rare diseases and increasingly on more prevalent conditions.
Geographic Base and Sector Classification
Headquartered in Cambridge, Massachusetts and listed on NASDAQ, Alnylam is a U.S.-based biotech with a growing global commercial footprint. It sits squarely in the innovation-heavy side of biotechnology.
Business Model Characteristics
The company combines product revenue, launch execution, and platform expansion with a deep RNAi pipeline. Investors watch adoption of approved medicines, label expansions, manufacturing scale, and the next wave of RNAi programs.
Position Within the Biotechnology Landscape
Alnylam occupies a top-tier position in platform biotech because it has already proved RNAi can work commercially. Compared with earlier-stage names, it has more durability, but it still reacts to regulatory and pipeline milestones.
Future catalysts
Alnylam’s near-term catalysts are Amvuttra growth in ATTR-CM, Zilebesiran development, and broader RNAi adoption in cardiometabolic and rare disease. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Alnylam Pharmaceuticals, Inc. (ALNY)?
Alnylam Pharmaceuticals, Inc. (ALNY) most recently closed at 216.12 USD, a -5.51% move versus the previous session.
What is the market cap of Alnylam Pharmaceuticals, Inc. (ALNY)?
Alnylam Pharmaceuticals, Inc. currently has a market capitalization of 38.2B USD on BioPharmSignal.
What does Alnylam Pharmaceuticals, Inc. do?
Alnylam Pharmaceuticals is the pioneer of RNA interference therapeutics and one of the most important platform biotech companies in the market. Its approved medicines and pipeline programs focus on rare diseases and increasingly on more prevalent conditions.
On which exchange is ALNY stock listed?
Alnylam Pharmaceuticals, Inc. (ALNY) is associated with NASDAQ, Cambridge, Massachusetts, Nucleic Acid Drugs.
What is ATTR-CM?
Alnylam’s near-term catalysts are Amvuttra growth in ATTR-CM, Zilebesiran development, and broader RNAi adoption in cardiometabolic and rare disease.
Which conditions is Alnylam Pharmaceuticals, Inc. targeting with ATTR-CM?
Alnylam Pharmaceuticals, Inc. is associated with rare disease, metabolic disease based on its company overview and current catalyst commentary.
How does Alnylam Pharmaceuticals, Inc. describe recent progress with ATTR-CM?
Alnylam’s near-term catalysts are Amvuttra growth in ATTR-CM, Zilebesiran development, and broader RNAi adoption in cardiometabolic and rare disease.
What is Alnylam?
Alnylam Pharmaceuticals is the pioneer of RNA interference therapeutics and one of the most important platform biotech companies in the market.